Policy | August 09, 2024
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
Expect the international business including CDMO business to pick-up in the second half of the financial year
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Subscribe To Our Newsletter & Stay Updated
